Literature DB >> 16762192

[Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].

Guo-yan Liu1, Quan-xin Qu, Ruo-ran Mi, Jing Qi.   

Abstract

OBJECTIVE: To study changes of cisplatin sensitivity by RNA interfering the excision repair cross-complementing (ERCC) 1 gene in ovarian cancer cell lines.
METHODS: The small interference RNA (siRNA) targeting ERCC1 gene was designed and synthesized by transcription in vitro, and transfected to ovarian cancer cell line ES-2. The mRNA and protein of ERCC1 were evaluated by means of RT-PCR, western blot and immunocytochemistry. The changes of cisplatin sensitivity after interference were examined by methyl thiazolyl tetrazolium (MTT) assay.
RESULTS: In ES-2 cell, the mRNA and protein levels of ERCC1 were dramatically decreased 24, 48 and 72 hours after transfection. The sensitivity to cisplatin of ES-2 cell line was increased by 53.88 times after disturbing the ERCC1 gene.
CONCLUSION: The sensitivity to cisplatin of ovarian cancer cell lines ES-2 could be enhanced by RNA interfering ERCC1 gene.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762192

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  2 in total

1.  MyD88 in DNA repair and cancer cell resistance to genotoxic drugs.

Authors:  Alain Kfoury; Katy Le Corf; Rana El Sabeh; Alexandra Journeaux; Bassam Badran; Nader Hussein; Serge Lebecque; Serge Manié; Toufic Renno; Isabelle Coste
Journal:  J Natl Cancer Inst       Date:  2013-06-13       Impact factor: 13.506

2.  ERCC1 expression status predicts the response and survival of patients with metastatic or recurrent cervical cancer treated via platinum-based chemotherapy.

Authors:  Hyewon Ryu; Ik-Chan Song; Yoon-Seok Choi; Hwan-Jung Yun; Deog-Yeon Jo; Jin Man Kim; Young Bok Ko; Hyo Jin Lee
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.